Testing a new treatment for early Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new drug called TML-6 for people with early Alzheimer's disease or mild cognitive impairment. It aims to see if the drug is safe and can help slow down memory and thinking problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 85 years old.
- You have been diagnosed with mild cognitive impairment or mild Alzheimer's dementia.
- You have a study partner (like a family member or friend) who can spend at least 10 hours a week with you and provide information about you.
- You are willing to have blood tests, brain scans (MRI), and possibly a PET scan.
- You have not taken anti-amyloid therapy before.
- You are not currently taking certain supplements like curcumin or ginkgo, or you can stop them a month before the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This program provides access to an investigational drug called TB006 for people with Alzheimer's disease or related dementias who have run out of standard treatment options. It aims to see if the drug is safe and helpful in a real-world setting.
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.